core1 trial: cg0070 plus pembrolizumab for bcg-unresponsive carcinoma-in-situ bladder cancer
Published 2 years ago • 100 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
1:55
durvalumab monotherapy for patients with bcg-unresponsive carcinoma-in-situ bladder cancer
-
1:45
mechanism of action of the adenovirus oncolytic virus cg0070 plus pembrolizumab in bladder cancer
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
4:59
cg0070 combined with pembro shows promising efficacy in patients with nmibc unresponsive to bcg
-
2:01
keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc
-
53:45
oligometastatic renal cancer and bcg-unresponsive non-muscle-invasive bladder cancer
-
1:47
current and upcoming clinical trials in bladder cancer
-
1:12
scott tagawa, md, on the study investigating nadofaragene firadenovec in bcg unresponsive nmibc
-
0:30
enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
-
51:36
treatment of high risk nmibc in era of bcg shortage - empire urology lecture series
-
6:08
immunotherapy approaches for nmibc
-
29:46
introduction to adstiladrin | gene therapy for bcg unresponsive nmibc
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
11:45
emerging treatments for bcg unresponsive non-muscle invasive bladder cancer
-
5:49
optimal therapy is intravesical
-
6:23
pembro monotherapy for participants with bcg–unresponsive hr nmibc shows anti-tumour activity
-
1:30:08
chemotherapy & immunotherapy options for genitourinary malignancies: a primer for urologists & apps
-
1:52
can atezolizumab succeed where bcg fails in bladder cancer?